Motif Bio

http://www.motifbio.com/ TICKER: MTFB     EXCHANGE: AIM

Motif Bio PLC is a drug discovery and development company targeting new antibiotic solutions. Modern medicine is under threat from antibiotic resistance, particularly for hospital-acquired infections (HAI). Motif has an opportunity to help strengthen the physician's toolbox for antibiotic-resistant bacteria.

LATEST REPORTS

 
Motif Bio - ED Investor Forum September 2015
Published: Sep 25 2015

Graham Lumsden, Chief Executive Officer, presents on behalf of Motif Bio and updates investors on Iclaprim.
 
Approval signals clear GAIN for Motif
Published: Jul 27 2015

Motif Bio is a clinical stage biopharma company specialising in developing novel antibiotics to combat life-threatening diseases caused by multi-drug resistant bacteria. 
Recent QIDP status for iclaprim in both serious skin and bacterial pneumonia indication is very significant, meaning that it benefits from a fast-track approval process and receives an extra 5 years of marketing exclusivity in the US (from the date of approval - H1'18 forecast) under Hatch-Waxman legislation (making a total of 10 years).
Motif next aims to initiate Phase 3 trials for iclaprim in 2015. FDA confirmed in April that two successful serious skin infection trials or one skin (ABSSSI) and one pneumonia (HABP) trial would be required for iclaprim's US approval. 
We raise our fair valuation range for this rapidly maturing company to £95m-£125m, through greater probability of product approval and launch (now 64% versus 50%) and a higher implied royalty rate (15% versus 12%) on our licensing model.
That current valuation mid point equates to 102p per share compared to the current 65p level. However, we would also remind investors that positive Phase 3 results should imply a multiplier for this figure, with potential M&A activity adding a further premium. 
 
Recording of CEO webinar now available
Published: Jun 11 2015

You can now hear the presentation given by CEO, Graham Lumsden, on the 10th June, as well as the ensuing Q&A with investors. 
To view simply click on the video below.
 
Opportunities to overcome antibiotic resistance
Published: May 12 2015

Motif Bio PLC (MTFB) is a drug discovery and development company targeting new antibiotic solutions. Modern medicine is under threat from antibiotic resistance, particularly for hospital-acquired infections (HAI). MTFB has an opportunity to help strengthen the physician's toolbox for antibiotic-resistant bacteria.

MTFB recently raised £2.8m listing on AIM to support steps towards a Phase 3 programme of its recently acquired novel antibiotic, iclaprim, in two significant HAI indication areas. These could be worth up to $1bn in worldwide revenues, and highly attractive to Big Pharma acquirers. Indeed, Motif has just been selected to present at the 2015 BIO International Convention, the world's largest biotech meeting.

The outcome of a recent meeting with the US FDA (on 14 April) confirmed that iclaprim is ready for the clinic. Motif is exploring additional sources of funding to support this programme to completion - including non-dilutive awards and grants, and corporate partnering.

There is a healthcare crisis imminent through lack of new antibiotics, so MTFB should enjoy worldwide government and regulatory support to help commercialise iclaprim (and other product candidates), benefit from a fast-track approval process and a potential 10 years of market exclusivity.

A successful partnering strategy and commercialisation outcome suggests forecasts that support a valuation in the range of £45m-£60m. Positive Phase 3 results should be a multiplier for this figure, with potential M&A activity adding a further premium.

ARCHIVE